Cost utility of telaprevir-PR versus boceprevir-PR and versus PR alone in chronic hepatitis C in the Netherlands

A Vellopoulou; M (Michel) van Agthoven; AG van der Kolk; Rob de Knegt; G Berdeaux; S Cure; F Bianic; M Lamotte

Cost utility of telaprevir-PR versus boceprevir-PR and versus PR alone in chronic hepatitis C in the Netherlands

A Vellopoulou, M (Michel) van Agthoven, AG van der Kolk, Rob de Knegt, G Berdeaux, S Cure, F Bianic, M Lamotte

Gastroenterology & Hepatology

Research output: Contribution to journal › Article › Academic › peer-review

10 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	647-659
Number of pages	13
Journal	Applied Health Economics and Health Policy
Volume	12
Publication status	Published - 2014

Research programs

EMC MM-04-20-02-A

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{26f03ba1e17f482ca75a8171a11dfea4,

title = "Cost utility of telaprevir-PR versus boceprevir-PR and versus PR alone in chronic hepatitis C in the Netherlands",

author = "A Vellopoulou and {van Agthoven}, {M (Michel)} and {van der Kolk}, AG and {de Knegt}, Rob and G Berdeaux and S Cure and F Bianic and M Lamotte",

year = "2014",

language = "Undefined/Unknown",

volume = "12",

pages = "647--659",

journal = "Applied Health Economics and Health Policy",

issn = "1175-5652",

publisher = "Springer International Publishing AG",

}

TY - JOUR

T1 - Cost utility of telaprevir-PR versus boceprevir-PR and versus PR alone in chronic hepatitis C in the Netherlands

AU - Vellopoulou, A

AU - van Agthoven, M (Michel)

AU - van der Kolk, AG

AU - de Knegt, Rob

AU - Berdeaux, G

AU - Cure, S

AU - Bianic, F

AU - Lamotte, M

PY - 2014

Y1 - 2014

M3 - Article

SN - 1175-5652

VL - 12

SP - 647

EP - 659

JO - Applied Health Economics and Health Policy

JF - Applied Health Economics and Health Policy

ER -